Clinical Trial

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-25; most recent amendment 2024-02-27.
Status change: Not Yet Recruiting → Recruiting 2024-02-27
Trial Details
NCT Number NCT05970666
Lead Sponsor The First Affiliated Hospital of Xiamen University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Adebrelimab, Hepatocellular Carcinoma, Transformation, Bevacizumab, TACE
Enrollment 71 participants
Start Date 2023-11-15
Primary Completion 2026-11-15 (estimated)
Study Completion 2026-11-15 (estimated)
Updated on ClinicalTrials.gov 2024-02-28